

Therapeutics for Glomerular and Autoimmune-related Kidney Diseases



Chinook Therapeutics is a **clinical-stage biotechnology company developing precision medicines for kidney diseases**. They are seeking to develop **therapeutics targeting molecular drivers of kidney disease progression**. The company is interested in leveraging its precision medicine approach by identifying **targets, mechanisms, and pathways with supporting biological validation data or genetic data** showing strong correlation with human kidney disease.

Approaches of Interest

- **Primary glomerular diseases** (e.g. IgAN, Alport syndrome, FSGS)
- **Autoimmune-related renal diseases** (e.g. lupus nephritis, systemic lupus erythematosus, membranous nephropathy, ANCA-associated vasculitis)
- **Rare or ultra-rare kidney disease indications** (e.g. ADTKD, cystinuria, primary hyperoxaluria), **nephrolithiasis** (kidney stone formation), **polycystic kidney disease**, and **renal transplant**
- **Novel genetic targets** are of interest, as well as drug-repurposing approaches
- **Novel approaches for targeted delivery to specific cell types or compartments of the kidney** are also of interest

Out of Scope

- Congenital diseases
- Diabetic nephropathy or diabetic kidney disease, acute kidney injury, renal fibrosis
- Disease complications (dialysis, anaemia, pruritus)

Developmental Stages of Interest





- Opportunities between lead optimisation and phase I are ideal but earlier stages of development will be considered
- Research should have biological validation or genetic data showing strong correlation with human kidney diseases
- Opportunities with *in vitro* and *in vivo* data supporting target, mechanism or pathway involvement are of interest, as well as development of novel animal models which recapitulate human kidney disease phenotypes

Submission Information and Opportunity for Collaboration

Non-confidential submissions of one page, 200-300 word briefs are encouraged along with any optional supplementary information e.g. relevant publications and patents.

Chinook Therapeutics is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, sponsored research agreements and research collaborations. Chinook has in-house R&D capabilities to advance early-stage programs towards IND enabling studies and into the clinic, and has a track record of long-term relationships with academia including co-development projects, consultancy agreements and academic advisory board positions.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Research projects
-  Spinout companies
-  Centres of excellence

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **8th August 2022 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

